SCHEMBL1258211

SCHEMBL1258211

Cc1ccc(C#N)c(=O)n1-c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 6/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NOTUM Q6P988 2/20 0.45
FAAH O00519 1/20 0.44
MGLL Q99685 1/20 0.44
HPGD P15428 3/20 0.43
HSD17B10 Q99714 3/20 0.43
PKM P14618 1/20 0.43
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
TDP2 O95551 1/20 0.41
GAA P10253 2/20 0.40
S1PR4 O95977 1/20 0.40
GLA P06280 1/20 0.40
S1PR1 P21453 1/20 0.40
METAP2 P50579 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1259381 0.87 KDM4E (0.48) PTGS1PTGS2ALDH1A1KDM4ENPSR1
SCHEMBL1259767 0.82 KDM4E (0.60) PTGS2ALDH1A1KDM4ENOTUMMGLL
SCHEMBL5759510 0.82 KDM4E (0.45) ALDH1A1KDM4ENPSR1HPGDHSD17B10
SCHEMBL1259164 0.81 KDM4E (0.46) PTGS2ALDH1A1KDM4ENPSR1NOTUM
SCHEMBL1259328 0.80 KDM4E (0.48) PTGS2ALDH1A1KDM4ENPSR1HPGD
SCHEMBL4306674 0.78 KDM4E (0.43) PTGS2ALDH1A1KDM4ENPSR1HPGD
SCHEMBL16720842 0.78 ALDH1A1 (0.59) PTGS1PTGS2ALDH1A1KDM4ENOTUM
SCHEMBL1259743 0.77 KDM4E (0.45) ALDH1A1KDM4ENPSR1NOTUMHPGD
SCHEMBL1258266 0.77 GLA (0.47) PTGS1PTGS2ALDH1A1KDM4EHSD17B10
SCHEMBL1260574 0.75 KDM4E (0.40) ALDH1A1KDM4EHPGDHSD17B10RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF ABL1, MAP4K2, MAP3K20 PTGS1 1785/4885PTGS2 1673/4885ALDH1A1 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.